S

Sanofi

Global pharma company; vaccines and R&D

Global Scientific Content Manager HEVA and PDMD

Full-TimePosted on 10/19/2026Deadline 11/28/26
No salary listed
Expert
Bachelor's
Hyderabad, Telangana, India
RemoteTravel is required as needed for business.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • More than 8 years of experience in the pharmaceutical or related healthcare industry, including 2–3 years understanding scientific publication and medical communications strategy, planning, and execution across drug development and post-launch products.
  • Strong cross-functional collaboration, stakeholder management, interpersonal communication, written and verbal communication, time management, peer review, critical evaluation, independent work, prioritization, strategic thinking, problem solving, leadership, planning, organization, negotiation, and innovation skills.
  • Knowledge of therapeutic areas, publication and medical communication processes, and/or project management.
  • Understanding of clinical trials, patient-reported outcomes, qualitative research methods, real-world evidence study design and execution, statistical methods, and reporting requirements.
  • Ability to critically review scientific literature, data, and written content for accuracy, tone, and logical flow.
  • Knowledge of industry guidelines for stakeholder engagement and interactions with healthcare providers.
  • Understanding of good publication practices and guidance, including GPP4 and ICMJE, the Sunshine Act, the Pharma Code of Conduct, and other data-communication guidance.
  • Familiarity with publication and medical communication management tools, including iEnvision, PromoMats, and customer relationship management tools.
  • An advanced degree in life sciences, pharmacy, a similar discipline, or a medical degree.
  • Excellent spoken and written English.
Responsibilities
  • Support development and execution of integrated scientific expert engagement, congress, medical education, dissemination, and multichannel engagement strategies for assigned therapeutic areas and products.
  • Execute scientific dissemination, expert engagement, and medical multichannel engagement plans for global and country teams.
  • Identify multichannel customer-facing initiatives that improve scientific and medical learning, patient care, and customer experience while incorporating patient-centric perspectives and patient-reported outcomes.
  • Track emerging digital technologies in healthcare and pharmaceutical industries and use proof-of-concept testing to evaluate ideas and channels.
  • Develop and expand international expert networks through key opinion leader mapping, including identification, profiling, and segmentation of experts, emerging leaders, and rising stars.
  • Maintain collaborative relationships with internal stakeholders, key opinion leaders, scientific and academic societies, patient associations, advocacy groups, medical communication companies, and strategy companies.
  • Attend medical meetings, advisory boards, outreach meetings, and key-institution engagements with experts, academic societies, and advocacy groups.
  • Manage and oversee scientific congresses and events, donations and other contributions, advisory board planning and organization, and compliance and transparency requirements.
  • Develop and oversee strategic scientific publication plans and operational medical communication activities for assigned products and disease areas, including patient-reported outcomes, qualitative patient studies, and real-world evidence outputs.
  • Plan content deliverables by reviewing clinical findings, disease burden, unmet needs, and patient-reported outcomes and proposing corresponding content.
  • Perform scientific review, quality control, scientific and clinical accuracy checks, and peer review of manuscripts, abstracts, posters, slide decks, and value communication documents.
  • Deliver medical communication resources, scientific publication projects, digital publication enhancements, internal education resources, and congress materials according to timelines, compliance policies, and budgets.
  • Provide oversight, quality control, scientific review, and project management for publication and medical communication projects.
  • Provide direction, editorial review, and guidance to internal and external scientific writers, stakeholders, and regional partners.
  • Maintain knowledge of international requirements, guidance, and tools associated with scientific publications and medical communications.
  • Inform global and local teams about the availability and relevance of developed content assets and analyze content usage data to improve medical content development.
  • Incorporate stakeholder and patient-community needs, patient burden, lived-experience insights, and identified gaps into medical and business strategies.
  • Support adoption of innovative content formats and processes and remain current with internal content evolution and industry trends.
  • Ensure activities comply with corporate standard operating procedures, policies, and applicable external scientific, legal, and regulatory standards.
  • Collaborate cross-functionally with HEVA, patient-driven medicines development, Global Medical Affairs, clinical teams, and other internal and external stakeholders.
  • Maintain alignment and transparency across teams while promoting synergy and avoiding duplicated effort.
  • Maintain relationships with medical affairs, HEVA/patient-driven medicines development, marketing, communications, regulatory affairs, medical scientific communities, healthcare professionals, and other stakeholders.
  • Oversee scientific review, quality assurance, and delivery of publications and medical education materials aligned with medical strategy, timelines, and quality standards.
  • Provide strategic inputs involving individuals and institutions that may support publications and medical communications.
  • Support publication and medical communication processes, document-review workflows, publication-needs analysis, regional publication plans, vendor deliverables, training delivery, and course-content improvement based on end-user feedback.
Desired Qualifications
  • Hands-on experience peer reviewing scientific manuscripts, qualitative patient research, or HEVA/patient-driven medicines development deliverables.
  • Scientific expertise in the assigned disease area.
  • Experience with digital or innovative technology.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...